High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreThe presence of more than one high-risk genetic abnormality…
The U.S. Food and Drug Administration (FDA) has agreed…
A first patient with relapsed/refractory multiple myeloma (RRMM)…
Researchers in Brazil have developed a large dataset of…
Regulators in the European Union (EU) have approved…
Abbvie is teaming up with China-based company…